(Q35740613)

10 August 2017

0 references

Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials (English)

1 reference

10 August 2017

1 reference

1 reference

Wei Zhang

1

1 reference

10 August 2017

Xue-yan Chen

2

1 reference

10 August 2017

Su-wen Su

3

1 reference

10 August 2017

Qing-zhong Jia

4

1 reference

10 August 2017

Tao Ding

5

1 reference

10 August 2017

Zhong-ning Zhu

6

1 reference

10 August 2017

Tong Zhang

7

1 reference

10 August 2017

publication date

9 August 2015

1 reference

10 August 2017

published in

Neurological Sciences

1 reference

10 August 2017

volume

37

1 reference

10 August 2017

issue

1

1 reference

10 August 2017

page(s)

57-65

1 reference

https://scigraph.springernature.com/pub.10.1007/s10072-015-2357-0

10 August 2017

exact match

0 references

cites work

Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Melatonin-dependent timing of seasonal reproduction by the pars tuberalis: pivotal roles for long daylengths and thyroid hormones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Melatonin and its analogs in insomnia and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Melatonin: a pleiotropic molecule regulating inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Inner retinal circadian clocks and non-visual photoreceptors: novel players in the circadian system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Chronobiotics--drugs that shift rhythms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Melatonin as a natural ally against oxidative stress: a physicochemical examination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Basic mechanisms involved in the anti-cancer effects of melatonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Pharmacology and physiology of melatonin in the reduction of oxidative stress in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Meta-analysis: melatonin for the treatment of primary sleep disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Sleep disorders in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Pharmacotherapies for sleep disturbances in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Melatonin for sleep disturbances in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Melatonin in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Sleep disturbances in Alzheimer's and Parkinson's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Effect of melatonin in selected populations of sleep-disturbed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

The Synergistic Relationship between Alzheimer's Disease and Sleep Disorders: An Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Role of melatonin supplementation in neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Treatment outcomes in REM sleep behavior disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Rapid Eye Movement Sleep Behavior Disorder and Neurodegenerative Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Comprehensive treatment of dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10072-015-2357-0

Melatonin fails to improve sleep or agitation in double-blind randomized placebo-controlled trial of institutionalized patients with Alzheimer disease

21 January 2018

1 reference

12 December 2020

A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease.

1 reference

12 December 2020

Oxidative damage in the central nervous system: protection by melatonin

1 reference

12 December 2020

Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial

1 reference

12 December 2020

Association of progranulin polymorphism rs5848 with neurodegenerative diseases: a meta-analysis

1 reference

12 December 2020

10.1007/S10072-015-2357-0

Identifiers

DOI

1 reference

10 August 2017

1 reference